Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

NCT04466137 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

398

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Myeloid Malignancy

Interventions

DRUG: YPEG-rhG-CSF
DRUG: YPEG-rhG-CSF
DRUG: rhG-CSF/PEG-rhG-CSF

Sponsor

Xiamen Amoytop Biotech Co., Ltd.

Collaborators

[object Object]